ABSTRACT
Inanimate motors, driven by the difference in surface tension, provide platforms for studying the physics of characteristic motion and mimicking the complex behaviors of biological systems. However, it is challenging to endow inanimate motors with high autonomy, with an emphasis on simulating the behavior of living organisms in response to external stimuli. Herein, by applying sodium chloride (NaCl) as an external stimulus, we achieve the regulation of motion mode and chemotaxis in a self-propelled camphor system. We present a comprehensive surface/interface understanding of motion bifurcation with the increase of concentration NaCl, i.e., continuous motion to no motion via oscillatory motion. The features of motions (the speed and frequency) and the mechanisms are elucidated depending on the concentrations of NaCl and sodium dodecyl sulfate (SDS). Furthermore, the characteristic motion and chemotaxis to the salt stimulus are correlated to the dynamic breaking/reforming of the surface tension balance and gradient-type distribution phenomenon triggered by dynamic camphor dissolution, surfactant adsorption /diffusion and camphor-surfactant interaction. This work sheds light on the typical motions of inanimate motors and scrutinizes the synergy between dual additives, which will boost the design of advanced self-propelled systems with nonlinear characteristic motion.
ABSTRACT
Background: Despite the rich proximity and vascularization to the pelvic organs, metastatic lesions to the penis are incredibly uncommon. Most primary tumors are genitourinary cancers, and rectal origins are rare. Only 56 cases of metastatic penile tumors have been reported since 1870. Several palliative or curative methods, such as chemotherapy, total penectomy, and radiotherapy, have been applied to treat this condition in previous cases; however, the patient prognosis is poor. Immunotherapy is a beneficial treatment approach for multiple cancers, and recent investigations have shown that it may be beneficial for patients with advanced penile cancer. Case Description: Herein, we report the case of a 59-year-old Chinese man who had metastatic adenocarcinoma in the penile tissue 3 years after rectal cancer resection. The patient presented with penile pain and dysuria for 6 months when he was 54 years old, and Immunohistochemical staining showed that the origin was the rectum after total penectomy. The patient received surgery, chemotherapy, radiotherapy, targeted therapy and immunotherapy positively and still survived for a further 4 years and 6 months following penectomy despite the late metastasis of rectal cancer. There are two major changes and progress after penectomy, all of which have undergone surgical treatment during continuous treatment and follow-up, the patient completed right inguinal lymphadenectomy when his right regional nodes metastasis was found 23 months after penectomy. While the patient suffered from radiation injury after 47 months after penectomy, which led to radiation necrosis and hip soft tissue infection, and the patient tended to lay prone instead of lying on the back because of the hip pain. The patient ultimately died of multiple organ failure. Conclusions: All of the previously reported cases of penile metastasis from rectal cancer since 1870 have been reviewed. Yet, the metastatic prognosis remains poor regardless of the treatment options, except for lesions where metastasis is only limited to the penis. We found that the patient may derive more benefit from strategic therapies including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy.
ABSTRACT
The ceramization of polymeric precursors via thermal treatment represents a simple, fast and highly efficient method for producing polymer-derived ceramics (PDCs). PDCs integrating two-dimensional (2D) materials attracted special interest because they combine the diverse functionalities of 2D materials (electrical conductivity and catalytic performance) with the excellent intrinsic properties of PDCs, such as high-temperature stability, oxidation and corrosion resistance. This review focuses on recent development of the composites integrating PDC and 2D materials (PDC-2D composites). The methods used to prepare those materials and the relationship between as-prepared structures and property or functionality are discussed in detail. Then, the applications of PDC-2D composites in electromagnetic wave absorption and shielding, energy storage, hydrogen evolution, and electrothermal devices are also addressed.
ABSTRACT
BACKGROUND: The study aimed to compare efficacy and safety of various immune checkpoint inhibitors for patients with advanced or metastatic esophageal squamous cell carcinoma (ESCC). METHODS: We searched Medline, Web of Science, Cochrane Central Register of Controlled Trials, Embase, Clinical Trials.gov and several international conference databases from January 1, 2000 to December 19, 2021. We conducted Bayesian network meta-analysis to assess the relative effects among treatments. Outcomes included overall survival (OS), progression-free survival (PFS), overall response rate and adverse events. RESULTS: Ten eligible trials with 5250 patients were included. Toripalimab and Camrelizumab plus chemotherapy were preferred to rank first on OS (probability, 61%) and PFS (probability, 37%) in the first-line setting, respectively. In refractory patients, Sintilimab and Camrlizumab were most likely to be ranked first on OS (probability, 37%) and PFS (probability, 94%). The toxicity related to immunotherapy was manageable in clinical trials. Camrelizumab and Nivolumab had the less adverse events of grade 3 or higher in the first and refractory setting, respectively. CONCLUSIONS: This study found that Toripalimab and Camrelizumab plus chemotherapy were likely to be the best option in terms of OS and PFS in the first-line setting for patients with advanced or metastatic ESCC respectively. Sintilimab and Camrelizumab were the preferred options for OS and PFS in refractory patients respectively. The toxicity of immunotherapy was different from conventional chemotherapy, but manageable in patients with ESCC. TRIAL REGISTRATION: PROSPERO registration number: (CRD 42021261554).
